Topical 5% Imiquimod Cream for Vulvar Paget's Disease: Clinical Efficacy, Safety and Immunological Response

Trial Profile

Topical 5% Imiquimod Cream for Vulvar Paget's Disease: Clinical Efficacy, Safety and Immunological Response

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Imiquimod (Primary) ; Lidocaine; Paracetamol
  • Indications Extramammary Paget disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Planned End Date changed from 1 Sep 2018 to 1 Jan 2019.
    • 07 Jun 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Jan 2018.
    • 27 Mar 2017 Planned End Date changed from 1 Jan 2021 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top